BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Nuance Pharma Secures NMPA Clearance For Pivotal Actair® Allergy Trial In China

NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients Nuance Pharma announced that the National Medical...

May 25, 2026 | News

Leads Biolabs Secures China Phase III Approval For Opamtistomig In First Line EP NEC Treatment

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibod...

May 20, 2026 | News

ImmunityBio Secures Exclusive US Rights To Tokyo Strain BCG To Address Chronic Bladder Cancer Treatment Shortage

Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo...

May 19, 2026 | News

Racura Oncology Receives Positive Safety Review Committee Recommendation To Advance CPACS Trial In Advanced Solid Tumours

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced soli...

May 18, 2026 | News

Sichuan Kelun-Biotech Biopharmaceutical Secures China IND Clearance For PD 1 x VEGF Bispecific SKB118 In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...

May 14, 2026 | News

Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the prelimina...

May 13, 2026 | News

Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreement...

May 13, 2026 | News

Rznomics Secures FDA RMAT Designation For RNA Editing Therapy RZ 001 In Liver Cancer

RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, ...

May 11, 2026 | News

Harbour BioMed Secures US FDA Clearance For Phase I Trial Of Bispecific Cancer Antibody HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

May 11, 2026 | News

Cartography Biosciences Secures Strategic Investment From Samsung Ventures To Advance Precision Oncology Pipeline

Cartography Biosciences and Samsung Ventures announced a strategic investment to support the advancement of Cartography’s differentiated oncology pip...

May 08, 2026 | News

Australia Registers PEDMARQSI As First Approved Therapy To Prevent Cisplatin Related Hearing Loss In Children

PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 ...

May 07, 2026 | News

Cellenkos Advances CK0802 Into Phase 1b 2a Trial Following FDA Clearance For Steroid Refractory GVHD

Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with s...

May 06, 2026 | News

Thermo Fisher Introduces Gibco CTS DynaXS Single Use Bioreactor For Scalable Cell Therapy Manufacturing

New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical productio...

May 05, 2026 | News

EnGeneIC Doses First Patient In Trial Targeting Recurrent Glioblastoma

EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...

May 05, 2026 | News

Stay Connected